US President Donald Trump is threatening to impose tariffs of up to 200% on imported generic medicines, a move that would directly impact Swiss pharmaceutical giant Sandoz.
The threat targets the supply chain for off-patent drugs, aiming to force production back to US soil.
Sandoz, the world’s leading generic drug manufacturer, is particularly exposed to the proposal.
The company has largely refrained from establishing new manufacturing facilities in the United States, relying instead on its global production network.
This strategic choice leaves the firm vulnerable to aggressive protectionist measures aimed at reshoring pharmaceutical manufacturing.
While Sandoz’s CEO has aligned with the Trump administration on the broader issue of lowering drug prices, he has expressed reservations about the necessity of building new plants in America.